Puma Biotechnology (PBYI) Stock Price, Quote, News & History | Benzinga

Puma Biotechnology Inc (PBYI) Stock Price, Quote, News & History

PBYINASDAQ

Trade with Public

Trade with Public

$8.77

-0.14-1.57%

Last update: Aug 10, 11:05 AM

Earnings: Q2 2026 Earnings were released on Thu Aug 6th, after the market close

Conference Call: The most recent conference call started at 4:30 PM, 4 days ago

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$8.85

Close

-

Volume / Avg.

99.40K / 315.53K

Day Range

$8.55 - $8.90

52 Wk Range

3.05 - 9.40

Market Cap

$446.39M

P/E Ratio

17.53

Dividend Yield

-

Exchange

NASDAQ

RSI

65

Short Interest

9.02%

Days to Cover

10.65

Recent Puma Biotechnology Inc News

Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute

A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment.

Vandana Singh

Puma Biotechnology's Q1 Earnings and Revenues Beat

Puma Biotechnology, Inc. (NASDAQ: PBYI) reported first-quarter 2024 adjusted loss of 5 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 16 cents. In the year-ago quarter, the company had reported adjusted earnings of 9 cents.

Zacks

Why Nanobiotix Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

Gainers Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) shares surged 39.3% to $0.6621 in pre-market trading after gaining around 14% on Wednesday.

Lisa Levin

Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront payment of $90 million.

Lisa Levin

Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.

Lisa Levin

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

41.15M

Investing Cash Flow (TTM)

-16.02M

Financing Cash Flow (TTM)

-45.34M

Free Cash Flow (TTM)

41.16M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-20.22M

Analyst Trends and Forecast

0

0

0

0

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.5

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$365.96M

PE Ratio (TTM)

17.53

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

2.00

PB Ratio (TTM)

3.28

Earnings Yield % (TTM)

5.70%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

8.10

Price / EBITDA (TTM)

10.25

Price / Free Cash Flow (TTM)

11.25

Book Value / Share

$2.72

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$44.45M

Total Cash

$36.54M

Debt to Equity

0.03

Issuance of Debt (TTM)

-$44.45M

Repayment of Debt (TTM)

-$44.45M

Key Statistics

Open

$8.85

Close

-

Volume / Avg.

99.40K / 315.53K

Day Range

$8.55 - $8.90

52 Wk Range

3.05 - 9.40

Market Cap

$446.39M

P/E Ratio

17.53

Dividend Yield

-

Exchange

NASDAQ

RSI

65

Short Interest

9.02%

Days to Cover

10.65

About

Sector

Health Care

Industry

Biotechnology

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for t...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Puma Biotechnology (PBYI) stock?

A

You can purchase shares of Puma Biotechnology (NASDAQ:PBYI) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Puma Biotechnology (PBYI) competitors?

A

Other companies in Puma Biotechnology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Puma Biotechnology (PBYI) stock?

A

Puma Biotechnology has a consensus price target of $6.50.

Q

What is the current price for Puma Biotechnology (PBYI)?

A

The stock price for Puma Biotechnology (NASDAQ: PBYI) is $8.77 last updated August 10, 2026 at 11:05 AM EDT.

Q

Does Puma Biotechnology (PBYI) pay a dividend?

A

There are no upcoming dividends for Puma Biotechnology.

Q

When is Puma Biotechnology (NASDAQ:PBYI) reporting earnings?

A

Puma Biotechnology does not have any upcoming earnings scheduled.

Q

Is Puma Biotechnology (PBYI) going to split?

A

There is no upcoming split for Puma Biotechnology.

Q

What sector and industry does Puma Biotechnology (PBYI) operate in?

A

Puma Biotechnology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.